BNP Paribas Exane Issues Positive Forecast for Corteva (NYSE:CTVA) Stock Price
by Doug Wharley · The Cerbat GemCorteva (NYSE:CTVA – Get Free Report) had its target price boosted by investment analysts at BNP Paribas Exane from $74.00 to $77.00 in a report issued on Wednesday,MarketScreener reports. BNP Paribas Exane’s price target indicates a potential downside of 3.84% from the stock’s current price.
A number of other equities analysts have also recently issued reports on CTVA. Mizuho raised their target price on shares of Corteva from $82.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Deutsche Bank Aktiengesellschaft increased their price target on Corteva from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Zacks Research lowered Corteva from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 20th. Citigroup upped their price objective on Corteva from $74.00 to $80.00 and gave the stock a “neutral” rating in a research note on Thursday, February 5th. Finally, The Goldman Sachs Group raised their target price on Corteva from $88.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. Fourteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Corteva currently has an average rating of “Moderate Buy” and a consensus price target of $86.62.
View Our Latest Research Report on Corteva
Corteva Stock Performance
Shares of CTVA stock traded down $1.70 on Wednesday, hitting $80.07. 202,263 shares of the stock traded hands, compared to its average volume of 3,953,527. The company’s fifty day moving average is $80.66 and its 200 day moving average is $72.48. Corteva has a 1-year low of $60.53 and a 1-year high of $85.63. The company has a market capitalization of $53.76 billion, a PE ratio of 47.15, a PEG ratio of 2.88 and a beta of 0.59. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96.
Corteva (NYSE:CTVA – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.88%. The firm had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.64 billion. During the same quarter in the previous year, the firm earned $1.13 earnings per share. The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities research analysts predict that Corteva will post 3.62 earnings per share for the current fiscal year.
Insider Activity at Corteva
In other news, insider Brian Titus sold 8,311 shares of the business’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the sale, the insider owned 8,090 shares of the company’s stock, valued at approximately $619,289.50. The trade was a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.15% of the company’s stock.
Hedge Funds Weigh In On Corteva
Large investors have recently made changes to their positions in the business. Activest Wealth Management raised its holdings in shares of Corteva by 118.3% in the 3rd quarter. Activest Wealth Management now owns 369 shares of the company’s stock worth $25,000 after purchasing an additional 200 shares in the last quarter. JPL Wealth Management LLC acquired a new stake in shares of Corteva during the 3rd quarter valued at $25,000. Westfuller Advisors LLC boosted its stake in shares of Corteva by 2,764.3% during the 1st quarter. Westfuller Advisors LLC now owns 401 shares of the company’s stock worth $34,000 after acquiring an additional 387 shares in the last quarter. Garton & Associates Financial Advisors LLC acquired a new position in shares of Corteva in the 4th quarter worth $27,000. Finally, Bank of Jackson Hole Trust purchased a new stake in shares of Corteva during the fourth quarter valued at $28,000. Institutional investors own 81.54% of the company’s stock.
About Corteva
Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.